(Oslo, 3. juni 2026) Statkraft og Elkem ASA har inngått en ny langsiktig kraftavtale som sikrer konkurransedyktig og forutsigbar krafttilgang til Elkems verk på Bjølvefossen, i Kvam kommune i Vestland. Avtalen gjelder for perioden 2031–2037 og sikrer levering av totalt 1 534 GWh til verket.
Questrade launches Custom Indexing — Canada's first personalized index portfolio with no management fees, giving investors full control without the cost.
VANCOUVER, BC, Aug. 12, 2025 /CNW/ - (TSX: MER) (Nasdaq-Stockholm: MER) – Meren Energy Inc. ("Meren" or the "Company") today published its financial and operating...
WASHINGTON, Aug. 11, 2025 /PRNewswire/ -- EarthEcho International announced today the 14 participants, ages 16-21, selected for an innovative ocean restoration program led by youth...
ROUGEMONT, Québec, 07 août 2025 (GLOBE NEWSWIRE) -- Industries Lassonde inc. (TSX : LAS.A) (« Lassonde » ou la « Société ») a annoncé aujourd'hui ses résultats financiers pour le deuxième trimestre de l’exercice 2025.
VANCOUVER, BC, Aug. 7, 2025 /CNW/ - (TSX: MER) (Nasdaq-Stockholm: MER) – Meren Energy Inc. ("Meren" or the "Company") will publish its financial and operating results, along with the...
Qualified Investors and Analysts Can Register at No Cost at www.enercomdenver.com
Deadline to Submit One-on-One Meeting Requests to Presenting Companies is Friday, August 8th
Registration still...
(Montreal, Canada/Oslo, Norge) – Statkraft har signert en avtale om å selge Enerfín Canada, selskapets fornybarportefølje i Canada, til Atlantica Sustainable Infrastructure Ltd. Transaksjonen omfatter medarbeiderne, vindparker i drift og en utviklingsportefølje.
Landmark 30th Anniversary EnerCom Denver – The Energy Investment Conference Announces Energy Transition and Emerging Technology Session Schedule
Qualified Investors and Analysts Can Register at...
Orrön Energy AB (“Orrön Energy”) publicerar den finansiella rapporten för det andra kvartalet 2025 på onsdagen den 6 augusti 2025 klockan 07.30, vilket följs av en webbpresentation klockan 14.00.
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.